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Abstract  
BACKGROUND: Diabetic nephropathy (DN) is known as an acute microvascular complexity as a 
subsequence progression in diabetes mellitus type 1 and 2. Many evidence pointed that the 
proinflammatory cytokine Interleukin (IL)-18 might be involved in the pathogenesis of DN.  
AIM: The current study aimed to evaluate the association of serum IL-18 and its promoter gene 
polymorphisms with diabetic nephropathy.  
METHODS: This study included 62 diabetic nephropathy patients (DN group) compared to 52 
diabetes mellitus patients (DM group). The two groups were subjected to anthropometry 
assessment, molecular studies including SNP genotyping by RFLP and finally statistical analysis.  
RESULTS: The assessment of the serum IL-18 level and the frequencies of its allele and 
haplotype: -137G/C, -607C/A and -656G/T among the DN and DM subjects revealed that -137G 
allele has significant variation between DN and DM subjects (about 80.8%, P = 0.05) but, no 
significant variation in -607 or -656 alleles IL-18 gene promoter.  
CONCLUSION: These data confirm the impact of high serum IL-18 and the haplotype of the 
polymorphism located in the promoter region of the IL-18 gene with the DN. 
 
 
 
 
 
 
Introduction 
 
Diabetic nephropathy (DN) is a chronic 
complication of both type 1 and 2 diabetes mellitus 
(DM) [1, 2]. The complications of this disease include 
kidney failure and high risk to macrovascular 
problems which may lead to death [2]. Not only 
diabetic kidney diseases such as Kimmelstiel Wilson 
disease but also, intercapillary glomerulonephritis 
include the redundant drain of protein into the 
urine, hypertension, and steadily defective kidney 
activity [3]. In severe Kimmelstiel-Wilson syndrome, 
end-stage renal disease, kidney failure, renal dialysis 
and the kidney transplant became their occurrence of 
order. 
However, the actual molecular process 
causing the DN is not extensively clear even though 
many classic processes and pathways have been 
suggested to have an impact on DN development. 
Recently new molecular and epigenetic mechanisms 
showed evidence that inflammation including secreted 
proinflammatory cytokines and chemokines is related 
to DN [4]. Several proinflammatory cytokines such as 
interleukins (IL-6, IL-8 and IL-18) and tumour necrosis 
factor-α (TNF-α) are raised in patients with DN [5]. 
The mode of action for increasing these 
proinflammatory cytokines is still unpredictable. The 
oxidative stress has a significant role in raising the 
nuclear factor-kappaB (NF-κB) [6]. 
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Interleukin-18 (IL-18) is a multiple phenotypic 
cytokines produced by activated monocytes, dendritic 
cells and glial cells and it shows impact in numerous 
inflammatory processes [7]. It belongs to the IL-1 
superfamily and it works with IL-12 to induce cell-
mediated immunity following infection with microbial 
products like lipopolysaccharide (LPS).The 
combination of these two cytokines  has been shown 
to inhibit the IL-4 dependent IgE and IgG1 production 
and enhance IgG2a production in B cells [8].  
Serum IL-18 levels have been showed 
increasing in patients with DN [9]. IL-18 is known to 
lead the production of other proinflammatory cytokines 
[10], endothelial apoptosis [11], upregulation of ICAM-
1 [12], and hyperhomocysteinemia [13]. Thus, IL-18 
might be an important factor not only in the 
atherosclerosis processing but also, in the 
development and progression of diabetic 
nephropathy. 
Two polymorphisms in the IL-18 gene 
promoter region at positions -607 and -137, seem to 
correlate effectively on the genotype and serum 
concentrations of IL-18 [14]. Hernesniemi et al. (2008) 
also reported that IL-18 promoter G-137C 
polymorphism is an important predictor of sudden 
cardiac death in patients with and without underlying 
coronary heart disease. In spite of the link between IL-
18 promoter polymorphism, diabetes and 
cardiovascular disease, the relation between an IL-18 
promoter polymorphism and cardiovascular disease 
has not been studied in diabetic nephropathy patients 
[15].  
Position of IL-18 gene is at chromosome 
4q13–21 and several polymorphisms in its promoter 
region have been identified as – 607(C/A) (dbSNP: 
rs1946518), -137(G/C) (dbSNP: rs187238) and - 
−656(G/T) [16]. These common polymorphisms have 
been shown to regulate the IL-18 production of 
monocytes and are associated with transcriptional 
activity of the IL-18 gene.  
This study aimed to determine the association 
of serum IL-18 level and its gene promoter 
polymorphism -607(C/A), -137(G/C) and -656(G/T) 
with diabetic nephropathy in the Saudi Arabia 
population as a step towards finding a reliable 
biomarker for diagnosis the DN disease. 
 
 
Material and Methods 
 
Subjects  
Fifty-two patients (40 male and 12 females) 
diagnosed with Diabetic nephropathy were selected 
from outpatient Clinic of General AL-Dawadmie 
Hospital KSA. The diagnosis of DN was done by 
microalbuminuria (30-300 mg/day) or 
macroalbuminuria (>300 mg/day) with or without a 
decrease in glomerular filtration rate (GFR) or arterial 
hypertension as described by Eknoyan et al., (2003) 
[17]. Sixty-two diabetic patients without evidence of 
renal affection were selected as a control group. Both 
groups were undergone a complete physical and 
clinical examinations and fasting blood samples were 
collected. This study was approved by the Local 
Medical Ethical Committee and according to their 
instructions. All patients included in the study gave 
written informed consent. Glycosylated haemoglobin 
(HbA1c), total cholesterol, high-density lipoprotein 
(HDL), low-density lipoprotein (LDL) and triglyceride 
(TG) were determined by standard biochemical 
methods.  
 
Serum IL-18 assay 
The IL-18 was determined in serum samples 
for each subject by enzyme-linked immune assay 
(ELISA) (MyBioSource, Cat. No. MBS396299 San 
Diego, California, USA) according to the 
manufacture's instruction. 
  
DNA extraction 
Genomic DNA was purified from whole blood 
samples with the QIAamp® DNA Blood Mini Kit, 
Holliston, MA, USA). DNA was eluted in 150 μl elution 
buffer and examined on 1% agarose gel and stored at 
–20°C for analysis.  
 
SNP genotyping and haplotypes 
reconstruction 
PCR-RFLP based method was used to detect 
polymorphism in an IL-18 gene, for each 
polymorphism, a specific PCR-RFLP was done. SNPs 
for, rs1946519 (−656G/T) and rs187238 (−137G/C) 
were done by using the method described previously 
by Folwaczny et al. (2005) [18] while the IL-18 -607 
polymorphism (C/A) was identified as described by 
Kumar et al. (2014) [19]. The primers used for 
detection are listed in (Table 1) and were ordered 
commercially from Sigma-Aldrich. PCR reactions were 
carried on a thermocycler (Bio-Rad, USA) using 2X 
master mix (Qiagen, Cat No. 206143 Valencia, USA) 
according to the manufacturer's instructions. The PCR 
amplified products were run on 1.5% agarose gel and 
the bands corresponding to the predicted size were 
cut and purified using the gel extraction kit (QIA quick 
columns, Qiagen, Cat No. 28104, Valencia,USA) 
following the manufacturer's instructions.  
 
Anthropometry assessment 
Anthropometric evaluation was performed for 
all patients in both groups. Body weight, height and 
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waist circumference were measured following the 
recommendations of the International Biological 
Program [20].  
Table 1: The primers used in polymerase chain reactions (PCR) 
for amplification the target region from IL-18 gene 
SNPs PCR primers 
Annealing 
temperature 
(°C) 
Restriction 
enzymes 
Fragment 
sizes (bp) 
−656 
(G/T) 
F:5'AGGTCAGTCTTTGCTATCATTCCAGG'3 
R:5'CTGCAACAGAAAGTAAGCTTGCGGAGA
GG'3 
 
60 Mwo I 
G: 96 + 24 
T: 120 
−137 
(G/C) 
F:5'CACAGAGCCCCAACTTTTTACGGCAGA
GAA'3 
R:5'GACTGCTGTCGGCACTCCTTGG'3 
 
60 Mbo II 
G: 116 + 39 
C: 155 
-607 
(C/A) 
F:5'TTCTGTTGCAGAAAGTGTAAAAATTTT'3 
R: 5'AAAGGATAGTTGATACAGGCCATT'3 
 
55 Dra I 
C: 154 
A: 125 +28 
 
Body weight was determined to the nearest 
0.01 kg using a Seca Scale Balance, with minimal 
wear and without shoes. Body height was measured 
to the nearest 0.1 cm using a Holtain portable 
Anthropometer. Waist circumference was measured 
at the level of the umbilicus with the standing position, 
the face directed forward, shoulders relaxed, and 
normal breathing by using non-stretchable plastic tape 
to the nearest 0.1 cm. Body mass index (BMI) was 
calculated as body weight divided by height squared 
(kg/m
2
 ). 
 
Statistical analysis 
Allele’s frequency, genotypes, Linkage 
disequilibrium and haplotypes were computed using 
the Arlequin software (version 3.1) and SNPstats 
(http://bioinfo.iconcologia.net/SN Pstats). Data was 
presented by means ± SD and percentages .The 
compiled data were computerised and analysed by 
SPSS V 12. The following tests of significance were 
used: t-test between means we used analyses mean 
difference, t-test between percentage to analyse 
percent difference and chi –square. A level of 
significance with p ˃ 0.005 was considered 
insignificant. 
 
Figure 1: PCR digestion for -137 polymorphism and -607 
polymorphism interleukin 18 genes. (A) line 1, -137 GC and lines 2 
and 3 -137 CC. M line: ϕx 174 Marker. (B) lines 1,2 and 3 – 607 TT. 
M line: ϕx 174 Marker  
 
 
Results  
In the present work, we analysed serum IL-18 
and three functional polymorphisms, -137G/C, -
607C/A and -656G/T at the promoter region of the 
IL18 gene in 62 DM and 52 DN patients Figure 1. 
General and clinical characteristics of all the subjects 
enrolled in this study are shown in Table 2. High 
serum IL-18 in DN patients in comparison to DM 
patients is observed as shown in (Table 2). There was 
significant positive co-relation between serum IL-18 
and HBA1c (R
2
 = 0.04, Figure 2). 
Table 2: General and laboratory characteristics of diabetes 
mellitus (DM) and diabetic nephropathy (DN) patients 
P –value DN 
(mean ± SD) 
DM 
(mean ± SD) 
Variable 
0.5 52.9 ± 9.15 52.8 ± 7.42 Age (years) 
-- 40/12 47/15 Sex (M/F) 
0.05* 28.3 ± 5.2 24.1 ± 5.1 BMI (kg/m
2
) 
0.005* 147.6 ± 27.9 133.6 ± 20.1 SBP (mmHg) 
0.005* 99.0 ± 15.2 80.1 ± 15.5 DBP (mmHg) 
0.005* 63.5% 40.3% Smoking habit % 
0.2 3.8 ± 1.3 3.6 ± 1.1 S. cholesterol (mmol/l) 
0.2 2.5 ± 1.1 2.3 ± 0.9 S. LDL (mmol/l) 
0.1 1.1 ± 0.4 1 ± 0.4 S. HDL (mmol/l) 
0.1 1.7 ± 0.6 1.5 ± 0.5 S. triglyceride (mmol/l) 
0.05* 47.3 ± 20.7 33.6 ± 12.3 S. urea (mg/dl) 
0.04* 130.5 ± 27.6 77.3 ± 21.1 S. creatinine (µmol/l) 
0.005* 68.8 ± 9.9 122.9 ± 15.3 Cr Cl (mL/min) 
0.04* 53.6 ± 13.3 25.4 ± 10.1 UACR (mg/mmol/L) 
0.01* 5.2 ± 1.5 3.1 ± 0.4 IL-18 (pg/ml) 
0.4 8.9 ± 2.1 8.4 ± 2.5 HbA1c 
-- 39 (75%) 57 (91.9%) Oral drug therapy 
-- 13 (25%) 5 (8.1%) Insulin drug therapy 
0.001* 373.7 ± 44.2 24.5 ± 5.2 Albuminuria (mg/24h) 
Cr Cl (Creatinine clearance) = 1.23 x (140-age in years) x weight (kg) / s. creatinine 
(µmol/l); * Significance between DM and DN patients (P ˂ 0.05). 
 
Comparing the allele frequencies of -137G/C, 
607C/A and 656G/T at the IL-18 promoters 
polymorphisms among the DM and DN patients was 
indicated in Table 3 and Table 4 revealed significant 
ratio of -137G allele (about 80.8%) more than C allele 
in DN (P ˂ 0.05) and in DN than DM patients (P ˂ 
0.05) while no significant variation between both 
groups in -607C/A and –656G/T polymorphism was 
observed. 
 
Figure 2: The relation between serum IL-18 and HbA1c 
 
Discussion  
 
The patients with diabetic nephropathy, in 
general, suffer from interruption of angiogenesis, 
permeability, apoptosis, and multiplication which could 
be as a result of inflammatory processes which 
affected the immune cells and cause the fibrotic 
phenomenon. This disease is characterised by the 
evolution from normoalbuminuria to microalbuminuria 
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followed by continuous diminish in the glomerular 
filtration rate (GFR), and high arterial blood pressure.  
Table 3: Comparing alleles of IL-18  promoter polymorphisms 
in DM and DN 
DN 
(%) 
DM 
(%) 
Alleles 
 
(48.1%) 
(51.9%) 
 
(51.6%) 
(48.4%) 
-656 
G 
T 
 
(50%) 
(50%) 
 
(46.8%) 
(53.2%) 
-607 
C 
A 
 
(19.2%)
**
 
(80.8%) 
 
(53.2%) 
(46.8%)
*
 
-137 
C 
G 
*: Significance between DM and DN in -137 G allele (P ˂ 0.05); **: Significance between C 
and G alleles of -137 in DN patients (P ˂ 0.05). 
 
IL-18 is a dominant inflammatory cytokine that 
induces IFN- [21] which in turn induces functional 
chemokine receptor expression in human mesangial 
cells [22]. 
Table 4: IL-18 Haplotypes distribution in diabetes mellitus (DM) 
and diabetic nephropathy (DN) 
DN 
N (%) 
DM 
N (%) 
Haplotypes 
3 (5.8 %)
*
 9 (14.5 %) -137C/-607A/-656G 
3 (5.8 %)
*
 10 (16.1 %) -137C/-607A/-656T 
2 (3.8 %)
*
 7 (11.3 %) -137C/-607C/-656G 
2 (3.8 %)
*
 7 (11.3 %) -137C/-607C/-656T 
10 (19.2%) 7 (11.3 %) -137G/-607A/-656G 
10 (19.2 %) 7 (11.3 %) -137G/-607A/-656T 
12 (23.1) 7 (11.3 %) -137G/-607C/-656G 
10 (9.2%) 8 (12.9 %) -137G/-607C/-656T 
*: Significance between DM and DN in the same haplotype (P ˂ 0.05). 
 
In addition, IL-18 leads to the production of IL-
1, and TNFand upregulation of ICAM-1, as well as 
apoptosis of endothelial cells [23]. IL-18 is 
constitutively expressed in renal tubular epithelia [17], 
infiltrating monocytes, macrophages, and T cells, 
endothelial cells of interstitial vessels along with 
proximal renal tubular cells, are potential sources of 
this cytokine [24]. In this study, IL-18 promoter 
polymorphism -137 is associated with the 
development of nephropathy in diabetic patients.  
The distribution of genotypes in the current 
study is similar to previous reports on Chinese 
subjects. For example, we found that the -137G allele 
(CG or GG genotypes) was more common in DN than 
C allele (CG or CC genotypes) which is similar to 
Dong et al., 2007 and Szeto et al., 2009. Dong et al., 
2007 found that GG, GC and CC genotypes at the -
137 site were 71.8%, 25.0% and 3.2% respectively 
but 78.7%, 20.0% and 1.3% respectively as reported 
by Szeto et al., 2009 [25, 26].  
Further, among white males, the C allele 
carriers at the -137 position had a high mortality risk 
but that with normal renal function and associated with 
high risk of cardiovascular disease [15]. A change at 
IL-18 gene  promoter at -137 from G to C can change 
the histone 4 transcription factor-1 (H4TF-1) nuclear 
factor binding site to a binding site for an unknown 
factor found in the granulocyte-monocyte colony 
stimulating factor (GM-CSF) promoter [19]. Similarly, 
we found that the -607(C/A) and -656(G/T) had no 
significant difference in DM and DN which is similar to 
data reported by Dong et al., 2007 and Szeto et al., 
2009 [25, 26]. Although other factors may also affect 
IL-18 gene expression, available data suggest that 
promoter polymorphism is the major determinant of IL-
18 production. Hyperglycemia stimulates the 
synthesis of IL-18 [27]. 
In the current study, it was found a statistically 
significant relationship between serum of IL-8 and the 
levels of glycosylated haemoglobin, in patients with 
diabetic nephropathy. Not only hyperglycemia but also 
albuminuria stimulates IL-18 expression in proximal 
tubular cells [28] which is correlated with our results.  
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